Gene editing technology developer Metagenomi advances research from UC Berkeley and has raised a series A co-led by Bayer.
Metagenomi, a US-based gene editing technology spinout of University of California (UC), Berkeley, has raised $64m in a series A round co-led by pharmaceutical and agricultural product maker Bayer.
Humboldt Fund co-led the round, which also featured Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital. Bayer invested through corporate venturing subsidiary Leaps by Bayer.
Founded in 2018, Metagenomi has developed Crispr-based technology intended to accurately edit DNA for use in gene and cell therapies. It screens thousands of genomes from different microorganisms using big data and computational algorithms to identify the best gene-editing techniques.
The spinout is based on work by co-founders Brian Thomas, a former application development manager at UC Berkeley and now CEO of Metagenomi, and Jillian Banfield, a professor whose responsibilities include leading the Microbial Research initiative within the Innovative Genomics Institute.
It raised $27.3m from undisclosed investors in August 2019, according…
